Welcome to our dedicated page for Centene Del SEC filings (Ticker: CNC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Centene Corporation (NYSE: CNC) SEC filings, offering insight into the company’s regulatory disclosures, financial communications, and governance updates. As a healthcare enterprise focused on government-sponsored and commercial healthcare programs, Centene uses filings such as Form 8-K to inform investors about material events, earnings information, and board changes.
Recent 8-K filings describe Centene’s participation in healthcare investor conferences, where management discusses the company’s financial outlook and the use of non-GAAP financial measures like adjusted diluted earnings per share. Other 8-Ks report quarterly financial results, the withdrawal or update of earnings guidance, and the resignation of directors along with resulting changes in the size of the board. These documents help investors understand how Centene evaluates its performance, plans operations, and manages corporate governance.
Through this filings page, users can review Centene’s current and historical submissions to the U.S. Securities and Exchange Commission, including annual and quarterly reports when available, as well as event-driven filings. Real-time updates from EDGAR are combined with AI-powered summaries that explain the key points of complex documents, helping readers interpret financial metrics, non-GAAP reconciliations, and narrative disclosures without wading through every page.
In addition to financial information, Centene’s filings may address topics such as regulatory considerations, risk factors related to government healthcare programs, and the company’s approach to non-GAAP reporting. For investors tracking CNC, this page serves as a central location to monitor new filings, understand the context of earnings announcements, and follow changes in leadership or guidance as they are formally reported to the SEC.
Centene Corporation director Robert K. Coughlin reported updated holdings of the company’s stock and options. On 12/31/2025, he acquired 729 shares of common stock at a stated price of $0, bringing his directly held common stock to 13,016.926 shares.
He also reports 30,054 shares held indirectly through a grantor retained annuity trust. His ownership includes 3,579 restricted stock units that are subject to vesting. In addition, he holds a stock option to buy 10,000 Centene common shares at an exercise price of $80.57, exercisable from 02/07/2025 until expiration on 02/07/2032.
Centene Corporation director Robert K. Burdick reported a small increase in his ownership of company stock. On 12/31/2025, he acquired 729 shares of common stock at $0, which typically reflects a vested equity award rather than an open-market purchase. After this transaction, he directly holds 273,093.924 shares of Centene common stock.
Burdick also reports 86,498 shares held indirectly through Burdick Family LLC, where he is a chief manager and disclaims beneficial ownership except for his economic interest. His reported ownership includes 3,579 restricted stock units that are still subject to vesting. In addition, he holds a stock option to buy 10,000 shares at $80.57 per share, exercisable starting 02/07/2025 and expiring on 02/07/2032.
Centene Corp director reports stock sales and remaining holdings. A Centene Corp (CNC) director sold 33,211 shares of common stock on 12/03/2025 at a weighted average price of $39.04 per share, and 32,796 shares on 12/04/2025 at $39.00 per share. After these transactions, the director directly beneficially owned 305,160.924 shares of Centene common stock, which include 3,579 restricted stock units that are subject to vesting requirements. In addition, the director had indirect beneficial ownership of 86,498 shares held by Burdick Family LLC, for which he is a chief manager and disclaims beneficial ownership except for his pecuniary interest. The filing also notes stock options covering 10,000 shares of common stock at an exercise price of $80.57, exercisable from 02/07/2025 until 02/07/2032.
CNC shareholder Kenneth Burdick filed a Form 144 notice covering a planned sale of 32,796 shares of common stock through Fidelity Brokerage Services LLC on 12/04/2025 on the NYSE. The filing lists an aggregate market value of about $1,279,044.00 for these shares, compared with 491,518,000 shares of the same class reported as outstanding.
The shares to be sold were acquired through restricted stock vesting from the issuer as compensation, including 31,916 shares on 07/23/2021 and 880 shares on 02/06/2024, both fully paid as compensation on the respective vesting dates. The notice also discloses that Burdick sold 33,211 shares of common stock during the past three months, on 12/03/2025, for gross proceeds of $1,296,621.24. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer.
Centene Corporation reaffirmed its full‑year 2025 outlook in advance of its appearance at the UBS 2025 Global Healthcare Conference. Management continues to expect a full year 2025 GAAP diluted loss per share not to exceed $(12.85) and a full year 2025 adjusted diluted EPS of at least $2.00.
The company will present on November 11, 2025 at 10:15 a.m. EST. A live audio webcast and replay will be available via Centene’s investor website. The update also reiterates the company’s use of non‑GAAP measures to isolate core operations alongside GAAP results.
FMR LLC filed Amendment No. 1 to a Schedule 13G reporting beneficial ownership of 0.7% of Centene Corp (CNC) common stock as of the event date 09/30/2025. The filing also lists Abigail P. Johnson as a reporting person.
FMR reports 3,345,475.62 shares beneficially owned, with 2,277,704.93 shares under sole voting power and 3,345,475.62 under sole dispositive power; shared voting and dispositive power are 0.00. The filing indicates ownership of five percent or less of the class.
The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing notes one or more other persons may have rights to dividends or sale proceeds, with no single person over five percent.
Norges Bank filed an amended Schedule 13G reporting a passive stake in Centene Corp (CNC). The filing shows beneficial ownership of 7,021,285 common shares, representing 1.4% of the class as of the event date 09/30/2025.
Norges Bank reports 5,758,942 shares with sole voting power and 0 with shared voting power. It has sole dispositive power over 4,496,598 shares and shared dispositive power over 1,262,343 shares. The position is certified as held in the ordinary course and not to change or influence control.
Centene Corporation furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025. The company issued a press release on October 29, 2025, and attached the full text as Exhibit 99.1 to a Form 8-K.
The disclosure was provided under Item 2.02 (Results of Operations and Financial Condition) and is expressly stated as “furnished” and not “filed,” which means it is not subject to Section 18 liability and is not incorporated by reference unless specifically noted. The Form 8-K was signed by Executive Vice President & Chief Financial Officer Andrew L. Asher.
Centene Corporation (CNC) reported Q3 2025 results with total revenues of
Premium revenue rose to
Goodwill decreased to
CNC: A holder filed a Form 144 notice to sell common stock. The filing lists 5,489 shares with an aggregate market value of $196,736.97, to be sold on or after 10/15/2025 on the NYSE through Merrill Lynch (Zionsville, IN).
The shares were acquired on 10/01/2025 via a stock bonus from Wayne S DeVeydt, in the same amount (5,489). Over the past three months, Wayne S DeVeydt previously sold 10,775 shares for gross proceeds of $314,545.12.
Shares outstanding were 491,133,000. This notice reflects an intended sale by or for the account named and does not represent an issuance by the company.
FAQ
What is the current stock price of Centene Del (CNC)?
What is the market cap of Centene Del (CNC)?
